However, therapeutic anti-tumor effects of MHC-II-restricted tumor-recognizing T cells have not been tested in clinical trials except for a single report that demonstrated that adoptive transfer of NY-ESO-1-specific CD4+ T cell clone in a melanoma patient led to complete remission20. The gene discussed is CD4; the disease is melanoma.